DUBLIN--(BUSINESS WIRE)--The "Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021" report has been added to ResearchAndMarkets.com's offering.
The Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2021 report provides comprehensive access to available records for over 2,300 manufacturing and supply deals, including contract documents where available.
This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology, device and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2014 to 2021.
The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
A supply or manufacturing agreement is normally between a product manufacturer and product owner in which an owner outsources the manufacture and supply of its product(s) to the service company in a defined territory.
Manufacturing and supply agreements provide a popular method of maximizing the value of a product launched into a market. The deals allow the product marketer to focus on its sales and marketing efforts whilst relying on a third party to manufacture and supply product on demand, enabling rapid response to market demands. It also ensures that the marketer does not need to invest in costly infrastructure and expertise ahead of knowing whether the product will be successful or sustainable.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,300 manufacturing and supply deals announced since 2014 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in manufacturing and supply deal making
2.1. Introduction
2.2. Difference between manufacturing and supply deals
2.3. Trends in manufacturing and supply deals since 2014
2.3.1. Manufacturing and supply deal making by year since 2014
2.3.2. Manufacturing and supply deal making by phase of development since 2014
2.3.3. Manufacturing and supply deal making by industry sector since 2014
2.3.4. Manufacturing and supply deal making by therapy area since 2014
2.3.5. Manufacturing and supply deal making by technology type since 2014
2.3.6. Manufacturing and supply deal making by most active company since 2014
2.3.7. When supply can be useful
2.4. Attributes of pure manufacturing and supply deals
2.5. Attributes of manufacturing and supply in multi-component deals
2.6. Reasons for including manufacturing and supply options in a multi-component deal
2.7. The future of manufacture and supply as part of multicomponent deals
Chapter 3 - Overview of manufacturing and supply deal structure
3.1. Introduction
3.2. Pure versus multi-component manufacturing deals
3.3. Pure manufacturing agreement structure
3.3.1. Example manufacturing agreements
3.3.1.a. Case study 1: Amyris Brazil - Biomin Nutricao Animal Do Brasil
3.3.1.b. Case study 2: Patheon - Orexigen Therapeutics
3.4. Manufacturing rights as part of a wider alliance agreement
3.4.1. Example multicomponent manufacturing clauses
3.4.1.a. Case study 3: Agenus Bio - NewVac
3.4.1.b. Case study 4: Elite Pharmaceuticals - Hi-Tech Pharmacal
Chapter 4 - Overview of supply deal structure
4.1. Introduction
4.2. Supply agreement structure
4.2.1. Example supply agreements
4.2.1.a. Case study 5: Omthera Pharmaceuticals - Catalent Pharma solutions
4.2.1.b. Case study 6: Endo Pharmaceuticals - Noramco
4.3. Supply rights as part of a wider alliance agreement
4.3.1. Example co-marketing right clauses
4.3.1.a. Case study 7: Auxilium Pharmaceuticals - Asahi Kasei
4.3.1.b. Case study 8: Durata Therapeutics - Hospira
Chapter 5 - Leading manufacturing and supply deals
5.1. Introduction
5.2. Top manufacturing and supply deals by value
Chapter 6 - Top 25 most active manufacturing and supply dealmakers
6.1. Introduction
6.2. Top 25 most active manufacturing and supply dealmakers
Chapter 7 - Manufacturing and supply deals contract directory since 2014
7.1. Introduction
7.2. Manufacturing and supply deals with contracts since 2014
Appendices
Appendix 1 - Manufacturing and supply deals by company A-Z
Appendix 2 - Manufacturing and supply deals by stage of development
Appendix 3 - Manufacturing and supply deals by deal type
Appendix 4 - Manufacturing and supply deals by therapy area
Appendix 5 - Manufacturing and supply deals by technology type
Appendix 6 -Deal type definitions
For more information about this report visit https://www.researchandmarkets.com/r/1v9nns
